- Home
- CRVS vs ATXS Comparison
CRVS vs ATXS Comparison
Compare CRVS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- ATXS
- Stock Information
- Founded
- CRVS 2014
- ATXS 2008
- Country
- CRVS United States
- ATXS United States
- Employees
- CRVS N/A
- ATXS N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- ATXS Health Care
- Exchange
- CRVS Nasdaq
- ATXS Nasdaq
- Market Cap
- CRVS 459.0M
- ATXS 424.4M
- IPO Year
- CRVS 2016
- ATXS 2015
- Fundamental
- Price
- CRVS $5.83
- ATXS $7.43
- Analyst Decision
- CRVS Strong Buy
- ATXS Buy
- Analyst Count
- CRVS 4
- ATXS 6
- Target Price
- CRVS $15.00
- ATXS $32.00
- AVG Volume (30 Days)
- CRVS 596.4K
- ATXS 313.6K
- Earning Date
- CRVS 11-11-2025
- ATXS 11-12-2025
- Dividend Yield
- CRVS N/A
- ATXS N/A
- EPS Growth
- CRVS N/A
- ATXS N/A
- EPS
- CRVS N/A
- ATXS N/A
- Revenue
- CRVS N/A
- ATXS N/A
- Revenue This Year
- CRVS N/A
- ATXS N/A
- Revenue Next Year
- CRVS N/A
- ATXS N/A
- P/E Ratio
- CRVS N/A
- ATXS N/A
- Revenue Growth
- CRVS N/A
- ATXS N/A
- 52 Week Low
- CRVS $2.54
- ATXS $3.56
- 52 Week High
- CRVS $10.00
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- CRVS 58.56
- ATXS 58.46
- Support Level
- CRVS $5.90
- ATXS $7.12
- Resistance Level
- CRVS $6.30
- ATXS $7.91
- Average True Range (ATR)
- CRVS 0.32
- ATXS 0.46
- MACD
- CRVS -0.00
- ATXS 0.09
- Stochastic Oscillator
- CRVS 53.92
- ATXS 72.63
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.